PMID- 34651026
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211016
IS  - 2297-055X (Print)
IS  - 2297-055X (Electronic)
IS  - 2297-055X (Linking)
VI  - 8
DP  - 2021
TI  - GRB10 rs1800504 Polymorphism Is Associated With the Risk of Coronary Heart 
      Disease in Patients With Type 2 Diabetes Mellitus.
PG  - 728976
LID - 10.3389/fcvm.2021.728976 [doi]
LID - 728976
AB  - Diabetic vascular complications are one of the main causes of death and 
      disability. Previous studies have reported that genetic variation is associated 
      with diabetic vascular complications. In this study, we aimed to investigate the 
      association between GRB10 polymorphisms and susceptibility to type 2 diabetes 
      mellitus (T2DM) vascular complications. Eight single nucleotide polymorphisms 
      (SNPs) in the GRB10 gene were genotyped by MassARRAY system and 934 patients with 
      type 2 diabetes mellitus (T2DM) were included for investigation. We found that 
      GRB10 rs1800504 CC+CT genotypes were significantly associated with increased risk 
      of coronary heart disease (CHD) compared with TT genotype (OR = 2.24; 95%CI: 
      1.36-3.70, p = 0.002). Consistently, levels of cholesterol (CHOL) (CC+CT vs. TT, 
      4.44 +/- 1.25 vs. 4.10 +/- 1.00 mmol/L; p = 0.009) and low density lipoprotein 
      cholesterin (LDL-CH) (CC+CT vs. TT, 2.81 +/- 1.07 vs. 2.53 +/- 0.82 mmol/L; p = 0.01) 
      in T2DM patients with TT genotype were significant lower than those of CC+CT 
      genotypes. We further validated in MIHA cell that the total cholesterol (TC) 
      level in GRB10-Mut was significantly reduced compared with GRB10-WT; p = 0.0005. 
      Likewise, the reversed palmitic acid (PA) induced lipid droplet formation in 
      GRB10-Mut was more effective than in GRB10-WT. These results suggest that 
      rs1800504 of GRB10 variant may be associated with the blood lipids and then may 
      also related to the risk of CHD in patients with T2DM.
CI  - Copyright (c) 2021 Yang, Qiu, Meng, Liu, Lin, Yang, Wang, Dong, Yuan, Zhou and He.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
FAU - Qiu, Wentao
AU  - Qiu W
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
AD  - College of Pharmacy, Jinan University, Guangzhou, China.
FAU - Meng, Qian
AU  - Meng Q
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
FAU - Liu, Mouze
AU  - Liu M
AD  - Department of Pharmacy, The Second Xiangya Hospital, Central South University, 
      Changsha, China.
FAU - Lin, Weijie
AU  - Lin W
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
FAU - Yang, Haikui
AU  - Yang H
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
FAU - Wang, Ruiqi
AU  - Wang R
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
FAU - Dong, Jiamei
AU  - Dong J
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
FAU - Yuan, Ningning
AU  - Yuan N
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
FAU - Zhou, Zhiling
AU  - Zhou Z
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
FAU - He, Fazhong
AU  - He F
AD  - Department of Pharmacy, Zhuhai People's Hospital (Zhuhai Hospital Affiliated With 
      Jinan University), Zhuhai, China.
LA  - eng
PT  - Journal Article
DEP - 20210928
PL  - Switzerland
TA  - Front Cardiovasc Med
JT  - Frontiers in cardiovascular medicine
JID - 101653388
PMC - PMC8505721
OTO - NOTNLM
OT  - GRB10
OT  - genetic variation
OT  - lipid metabolism
OT  - type 2 diabetes mellitus
OT  - vascular complications
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/10/16 06:00
MHDA- 2021/10/16 06:01
PMCR- 2021/01/01
CRDT- 2021/10/15 06:39
PHST- 2021/06/23 00:00 [received]
PHST- 2021/09/02 00:00 [accepted]
PHST- 2021/10/15 06:39 [entrez]
PHST- 2021/10/16 06:00 [pubmed]
PHST- 2021/10/16 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fcvm.2021.728976 [doi]
PST - epublish
SO  - Front Cardiovasc Med. 2021 Sep 28;8:728976. doi: 10.3389/fcvm.2021.728976. 
      eCollection 2021.